MSF warns on EU/India trade talks

18 January 2016
drugs_pills_tablets_big

As reported in Indian media, senior officials from the European Commission and India are expected to meet today in Brussels to hold talks on resuming negotiations on the proposed European Union-India free trade agreement.

The international medical humanitarian organization Médecins Sans Frontières (MSF) warned that India must resist European Union pressure to include harmful provisions on intellectual property that could restrict access to medicines for people in developing countries.

EU-India free trade agreement (FTA) talks began in 2007 and have largely stalled since 2013 because of several contentious issues including intellectual property rights. These include provisions that could restrict the production, sale and export of affordable life-saving medicines made in India, upon which millions of people in developing countries rely.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics